Nuvectis Pharma (NVCT) News Today $7.47 -0.42 (-5.32%) (As of 10/31/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 November 2021 Time Period Nuvectis Pharma (NVCT) Gets a Buy from Roth MKMOctober 29 at 1:48 AM | markets.businessinsider.comNuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2024 AACR-NCI-EORTC Symposium on Molecular Targets and Cancer TherapeuticsOctober 24, 2024 | finance.yahoo.comAnalyzing Nuvectis Pharma (NASDAQ:NVCT) and AbbVie (NYSE:ABBV)October 22, 2024 | americanbankingnews.comNuvectis Pharma to Participate in the 3rd Annual ROTH Healthcare Opportunities ConferenceOctober 7, 2024 | finance.yahoo.comNuvectis Pharma (NASDAQ:NVCT) Stock Quotes, Forecast and News SummaryOctober 6, 2024 | benzinga.comROTH to Host 3rd Annual Healthcare Opportunities Conference on October 9 in New York CityOctober 2, 2024 | markets.businessinsider.comPESG Releases Report on Nuvectis Pharma: With Summit Therapeutics Threatening to Dethrone Merck's Keytruda, Nuvectis' NXP900 is One to WatchSeptember 16, 2024 | finance.yahoo.comNuvectis Pharma (NASDAQ:NVCT) Trading Down 8.5%Nuvectis Pharma (NASDAQ:NVCT) Trading Down 8.5%September 11, 2024 | marketbeat.comNuvectis Pharma to Present at the H.C. Wainwright 26th Annual Global Investment ConferenceSeptember 5, 2024 | finance.yahoo.comNuvectis Shares Rally After Ovarian Cancer Drug Gets FDA's Orphan Drug DesignationAugust 29, 2024 | marketwatch.comNuvectis's NXP800 Granted FDA Orphan Drug Designation For ARID1a-Deficient Ovarian CancersAugust 29, 2024 | markets.businessinsider.comNuvectis Pharma Announces Orphan Drug Designation Granted by the FDA for NXP800 for the Treatment of ARID1a-deficient Ovarian, Fallopian Tube, and Primary Peritoneal CancersAugust 29, 2024 | globenewswire.comPositive Signs As Multiple Insiders Buy Nuvectis Pharma StockAugust 28, 2024 | finance.yahoo.comQ3 2024 EPS Estimates for Nuvectis Pharma, Inc. Increased by HC Wainwright (NASDAQ:NVCT)Nuvectis Pharma, Inc. (NASDAQ:NVCT - Free Report) - Stock analysts at HC Wainwright boosted their Q3 2024 earnings per share estimates for shares of Nuvectis Pharma in a research note issued to investors on Tuesday, August 6th. HC Wainwright analyst J. Pantginis now expects that the company willAugust 9, 2024 | marketbeat.comNuvectis Pharma, Inc. Reports Second Quarter 2024 Financial Results and Business HighlightsAugust 6, 2024 | globenewswire.comNuvectis Pharma (NASDAQ: NVCT): 5 Reasons to Keep this Pharma Disruptor on Your RadarAugust 2, 2024 | msn.com5 Reasons Why Nuvectis Pharma (NASDAQ: NVCT) Is a Biopharma Innovator to WatchAugust 1, 2024 | msn.comNuvectis Pharma, Inc. (NASDAQ:NVCT) Short Interest UpdateNuvectis Pharma, Inc. (NASDAQ:NVCT - Get Free Report) was the recipient of a significant decrease in short interest in the month of July. As of July 15th, there was short interest totalling 884,200 shares, a decrease of 18.1% from the June 30th total of 1,080,000 shares. Approximately 12.0% of the shares of the company are short sold. Based on an average trading volume of 96,000 shares, the days-to-cover ratio is presently 9.2 days.July 28, 2024 | marketbeat.comInsiders hold 65% of Nuvectis Pharma, Inc. (NASDAQ:NVCT), and they've been buying recentlyJuly 28, 2024 | finance.yahoo.comNuvectis Pharma Stands Out as a Unique Innovator in the Fast-Growing Precision Medicine MarketJuly 19, 2024 | theglobeandmail.com7 Penny Biotech Stocks to Triple Your InvestmentMay 28, 2024 | investorplace.comThe Veteran Pharma Founders That Keep Buying Their Own NASDAQ StockMay 20, 2024 | entrepreneur.comNuvectis Pharma: An Interesting Early Pipeline Does Not Justify A BuyMay 16, 2024 | seekingalpha.comNuvectis Pharma, Inc. (NASDAQ:NVCT) CEO Acquires $13,075.60 in StockMay 16, 2024 | insidertrades.comNuvectis Pharma, Inc. to Present at the H.C. Wainwright BioConnect Investor ConferenceMay 16, 2024 | globenewswire.comInsider Buying: Nuvectis Pharma, Inc. (NASDAQ:NVCT) CEO Purchases 1,940 Shares of StockNuvectis Pharma, Inc. (NASDAQ:NVCT - Get Free Report) CEO Ron Bentsur purchased 1,940 shares of the firm's stock in a transaction that occurred on Tuesday, May 14th. The stock was acquired at an average price of $6.74 per share, for a total transaction of $13,075.60. Following the completion of the purchase, the chief executive officer now owns 3,246,424 shares of the company's stock, valued at $21,880,897.76. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.May 15, 2024 | marketbeat.comInsider Buying: Nuvectis Pharma, Inc. (NASDAQ:NVCT) CEO Acquires 2,000 Shares of StockMay 14, 2024 | insidertrades.comNuvectis Pharma, Inc. (NASDAQ:NVCT) CEO Ron Bentsur Acquires 2,000 SharesNuvectis Pharma, Inc. (NASDAQ:NVCT - Get Free Report) CEO Ron Bentsur acquired 2,000 shares of the business's stock in a transaction that occurred on Friday, May 10th. The stock was purchased at an average price of $6.40 per share, for a total transaction of $12,800.00. Following the acquisition, the chief executive officer now directly owns 3,244,484 shares in the company, valued at approximately $20,764,697.60. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.May 13, 2024 | marketbeat.comNuvectis Pharma, Inc. Expected to Post Q2 2024 Earnings of ($0.23) Per Share (NASDAQ:NVCT)Nuvectis Pharma, Inc. (NASDAQ:NVCT - Free Report) - Analysts at Roth Capital increased their Q2 2024 EPS estimates for shares of Nuvectis Pharma in a research report issued on Tuesday, May 7th. Roth Capital analyst J. Aschoff now forecasts that the company will post earnings per share of ($0.23)May 10, 2024 | marketbeat.comFY2028 EPS Estimates for Nuvectis Pharma, Inc. (NASDAQ:NVCT) Boosted by Roth CapitalNuvectis Pharma, Inc. (NASDAQ:NVCT - Free Report) - Research analysts at Roth Capital increased their FY2028 earnings estimates for Nuvectis Pharma in a research report issued to clients and investors on Tuesday, May 7th. Roth Capital analyst J. Aschoff now anticipates that the company will postMay 9, 2024 | marketbeat.comStrong Buy Rating for Nuvectis Pharma on Robust Financials and Promising Oncology Drug TrialsMay 8, 2024 | markets.businessinsider.comNuvectis Pharma (NASDAQ:NVCT) Earns Buy Rating from HC WainwrightHC Wainwright restated a "buy" rating and issued a $21.00 price objective on shares of Nuvectis Pharma in a report on Wednesday.May 8, 2024 | marketbeat.comNuvectis Pharma Inc Reports Q1 2024 Financial OutcomesMay 8, 2024 | finance.yahoo.comNVCT Stock Earnings: Nuvectis Pharma Beats EPS for Q1 2024May 7, 2024 | investorplace.comIs Nuvectis Pharma (NASDAQ:NVCT) In A Good Position To Deliver On Growth Plans?April 17, 2024 | finance.yahoo.comNuvectis Pharma, Inc. to Post Q1 2024 Earnings of ($0.39) Per Share, HC Wainwright Forecasts (NASDAQ:NVCT)Nuvectis Pharma, Inc. (NASDAQ:NVCT - Free Report) - Investment analysts at HC Wainwright issued their Q1 2024 EPS estimates for shares of Nuvectis Pharma in a note issued to investors on Monday, April 8th. HC Wainwright analyst J. Pantginis expects that the company will post earnings of ($0.39) pApril 11, 2024 | marketbeat.comAnalysts Offer Insights on Healthcare Companies: Nuvectis Pharma (NVCT) and Invivyd (IVVD)April 8, 2024 | markets.businessinsider.comNuvectis Pharma, Inc.: Nuvectis Pharma's NXP900 Demonstrates Robust Activity in Non-Small Cell Lung Cancer Cell LinesApril 8, 2024 | finanznachrichten.deNuvectis Pharma: Data Confirms Robust Activity Of NXP900 - Quick FactsApril 8, 2024 | markets.businessinsider.comNuvectis Pharma's NXP900 Demonstrates Robust Activity in Non-Small Cell Lung Cancer Cell LinesApril 8, 2024 | finance.yahoo.comNuvectis Pharma's NXP900 Demonstrates Robust Activity in Non-Small Cell Lung Cancer Cell LinesApril 8, 2024 | globenewswire.com5 Healthcare Stocks to Buy for 2024April 2, 2024 | investorplace.comInsider Buys Additional US$51k In Nuvectis Pharma StockMarch 21, 2024 | finance.yahoo.comInsider Buying: Nuvectis Pharma, Inc. (NASDAQ:NVCT) CEO Purchases 5,000 Shares of StockMarch 20, 2024 | insidertrades.comNuvectis Pharma, Inc. (NASDAQ:NVCT) CEO Purchases $51,450.00 in StockNuvectis Pharma, Inc. (NASDAQ:NVCT - Get Free Report) CEO Ron Bentsur purchased 5,000 shares of Nuvectis Pharma stock in a transaction on Monday, March 18th. The stock was bought at an average cost of $10.29 per share, with a total value of $51,450.00. Following the transaction, the chief executive officer now directly owns 3,242,484 shares of the company's stock, valued at $33,365,160.36. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.March 19, 2024 | marketbeat.comNuvectis Pharma Announces Upcoming Presentations at the 2024 American Association for Cancer Research MeetingMarch 19, 2024 | globenewswire.comNuvectis reports initial data from Phase Ib ovarian cancer trialMarch 15, 2024 | msn.comNuvectis Pharma Shares Rise 11% After Positive Preliminary Data for Cancer TreatmentMarch 15, 2024 | marketwatch.comNuvectis Pharma to Present at the 36th Annual Roth ConferenceMarch 15, 2024 | globenewswire.comTrading was temporarily halted for "NVCT" at 09:03 AM with a stated reason of "LULD pause."March 14, 2024 | marketbeat.com Get Nuvectis Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for NVCT and its competitors with MarketBeat's FREE daily newsletter. Email Address [625,000% Gain] – Are You Ready for the Next Altcoin Boom? (Ad)All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen. Register for the FREE Workshop Now & get $10 in Bitcoin NVCT Media Mentions By Week NVCT Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. NVCT News Sentiment▼0.180.68▲Average Medical News Sentiment NVCT News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. NVCT Articles This Week▼11▲NVCT Articles Average Week Get Nuvectis Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for NVCT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies ALGS News AURA News QTTB News SLN News ARCT News KALV News PRTC News TERN News CRVS News ALT News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:NVCT) was last updated on 10/31/2024 by MarketBeat.com Staff From Our PartnersTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsoredtop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligen...Traders Agency | SponsoredNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | Sponsored“Buffett Indicator” Predicts 62% Stock Market CrashThe last time the "Buffett Indicator" flashed this red was in 2000 - right before the market crashed 50%.Behind the Markets | SponsoredTrump or Kamala? It may come down to this strange twist…Could this be the key to America's second coming? A strange resurrection born in the hollers of Appalachia? ...Porter & Company | Sponsored625,000% GainThe recent pullback in the crypto markets has left many investors in full-on panic mode, convinced the bull ru...Crypto Swap Profits | SponsoredGold at $2,600... But This Stock Gives You More for Under $20Gold just soared over $2,600 an ounce. But what if I told you there's a way to get exposure to MORE than an...Monument Traders Alliance | SponsoredCNBC’s ‘Prophet’ issues urgent Fed warning"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nuvectis Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Nuvectis Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
